本页面由Tiger Trade Technology Pte. Ltd.提供服务

诺和诺德

36.33
-0.5600-1.52%
盘后36.450.1200+0.33%17:17 EDT
成交量:1,619.57万
成交额:5.95亿
市值:1,612.71亿
市盈率:10.03
高:37.39
开:37.15
低:36.23
收:36.89
52周最高:81.44
52周最低:35.85
股本:44.39亿
流通股本:31.88亿
量比:0.77
换手率:0.51%
股息:1.72
股息率:4.74%
每股收益(TTM):3.62
每股收益(LYR):3.62
净资产收益率:60.70%
总资产收益率:17.43%
市净率:5.65
市盈率(LYR):10.03

数据加载中...

2026/02/04

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/06/27

员工持股计划

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2025/06/27

员工持股计划

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2025/05/30

关联方拟减持公告

Form 144 | Innate Pharma SA 10% 股东 Novo Nordisk A/S 拟减持921897股,总价约197万美元
2025/02/05

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/06/21

员工持股计划

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2024/06/21

员工持股计划

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2024/01/31

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/11/24

SEC问询函

Form CORRESP - Correspondence
2023/11/09

SEC问询函

Form CORRESP - Correspondence
2023/10/20

SEC问询函

Form CORRESP - Correspondence
2023/09/29

SEC问询函

Form CORRESP - Correspondence
2023/09/13

SEC问询函

Form CORRESP - Correspondence
2023/06/28

员工持股计划

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2023/06/28

员工持股计划

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2023/02/01

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/06/28

员工持股计划

11-K [Paper] - Annual report of employee stock purchase, savings and similar plans
2022/06/28

员工持股计划

11-K [Paper] - Annual report of employee stock purchase, savings and similar plans
2022/03/24

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2022/02/02

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]